Abstract:Background: Few pharmacodynamics studies to date have evaluated the efficacy and safety of polymyxin B (PMB) in treating patients with bloodstream infections (BSIs) in China. Methods: Patients with BSIs were identified using an antimicrobial surveillance network, and their pathogens were isolated. Patients were treated with a loading dose of PMB followed by either a weight-based or weight-independent maintenance dose. Monte Carlo simulation was utilized to calculate the probability of target attainment (PTA) and cumulative fraction of response (CFR) against Gram-negative organisms in patients with normal or decreased renal function. Results: A total of 10,066 Gram-negative organisms, including 5500 Escherichia coli (Eco), 2519 Klebsiella pneumoniae (Kpn), 501 Acinetobacter baumannii (Aba), were isolated from patients with BSIs. Although these strains were highly resistant to carbapenem, they remained susceptible to PMB. Among patients with renal impairment (mean CrCL, 42 mL/min), a PMB 2.5 mg/kg loading dose followed by a maintenance dose of 60 mg ql2h reached >= 90% PTA against isolates with an M1C of 2 mg/L, with a low risk of toxicity. Among patients with normal renal function (mean CrCL, 123 mL/min), all simulated regimens showed PTAs of 25-80%. A weight-based loading dose followed by either a weight-based or weight-independent maintenance dose showed a promising CFR, especially in patients with renal impairment, with CFRs >= 90% against carbapenem-resistant Eco, Kpn, and Aba. Simulated regimens showed a disappointing CFR (<80%) against carbapenem-resistant Pae in patients with normal renal function. Based on the optimal balance of efficacy and toxicity, a fixed maintenance dose of 60 mg q12h among patients with renal impairment yielded a CFR similar to regimens based on total body weight and was associated with a probability of toxicity (12.5%) significantly lower than that of simulations based on total body weight. Among patients with normal renal function, a weight-based maintenance dose of 1.25 mg/kg q12h achieved a higher CFR than a fixed maintenance dose, without significantly increasing toxicity. Conclusion: A 2.5 mg/kg loading dose of PMB is optimal, regardless of renal function. A fixed maintenance dose of 60 mg q12h is recommended for empirical treatment of patients with renal impairment infected with Eco, Kpn, and Aba, whereas a weight-based maintenance dose of 1.25 mg/kg is recommended for patients with normal renal function.

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against <i>Enterobacteriaceae</i>

Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae.

Physiologically Based Pharmacokinetic-Pharmacodynamic Evaluation of Meropenem in CKD and Hemodialysis Individuals

An established LC-MS/MS method and a developed PK model for the study of pharmacokinetic properties of benapenem in infected mice

Optimal Dosing Regimen of Biapenem in Chinese Patients with Lower Respiratory Tract Infections Based on Population Pharmacokinetic/pharmacodynamic Modelling and Monte Carlo Simulation

Evaluation of Biapenem Regimens in Treatment of Gram-Negative Bacterial Infections with Monte Carlo Simulation

Population Pharmacokinetics, Dosing Optimization and Clinical Outcomes of Biapenem in Patients with Sepsis

Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model

Cefepime, Not Piperacillin/Tazobactam Use, for Empirical Treatment of Bloodstream Infections Caused by Enterobacter Spp.: Results from a Population Pharmacokinetic/pharmacodynamic Analysis.

Efficacy and Safety of Biapenem Against Lower Respiratory Tract Infections in Elderly Chinese Patients and Optimal Dosing Regimen Based on Pharmacokinetic/pharmacodynamic Analysis

Pharmacodynamic Target Attainment of Seven Antimicrobials Against Gram-negative Bacteria Collected from China in 2003 and 2004.

Pharmacokinetic/pharmacodynamic (PK/PD) of Tebipenem against Klebsiella pneumoniae in Murine Thigh Infection Model

Model-Informed Drug Development of New Cefoperazone Sodium and Sulbactam Sodium Combination (3:1): Pharmacokinetic/Pharmacodynamic Analysis and Antibacterial Efficacy Against Enterobacteriaceae.

Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.

Choosing Optimal Antibiotics for the Treatment of Patients Infected with Enterobacteriaceae: A Network Meta-analysis and Cost-Effectiveness Analysis

Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China

Antibacterial Effect Evaluation of Moxalactam Against Extended-Spectrum Β-Lactamase-producing Escherichia Coli and Klebsiella Pneumoniae with in Vitro Pharmacokinetics/pharmacodynamics Simulation

Development of an effective meropenem/KPC-2 inhibitor combination to combat infections caused by carbapenem-resistant Klebsiella pneumoniae

Pharmacokinetics and Safety of Doripenem in Healthy Chinese Subjects and Monte Carlo Dosing Simulations.

Analysis of factors related to clinical efficacy of biapenem in bacteria infected patients

Pharmacokinetic/pharmacodynamic study of tebipenem pivoxil against Klebsiella pneumoniae in murine lung infection model